A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes

Guo, Y.; Huang, L.; Zhang, G.; Yao, Y.; Zhou, H.; Shen, S.; Shen, B.; Li Bo; Li Xin; Zhang, Q.; Chen, M.; Chen, D.; Wu, J.; Fu, D.; Zeng, X.; Feng, M.; Pi, C.; Wang, Y.; Zhou, X.; Lu, M.; Li Yarong; Fang, Y.; Lu, Y.; Hu, X.; Wang, S.; Zhang, W.; Gao, G.; Adrian, F.; Wang, Q.; Yu, F.; Peng, Y.; Gabibov, A.G.; Min, J.; Wang, Y.; Huang, H.; Stepanov, A.; Zhang, W.; Cai, Y.; Liu, J.; Yuan, Z.; Zhang, C.; Lou, Z.; Deng, F.; Zhang, H.; Shan, C.; Schweizer, L.; Sun, K.; Rao, Z.

Статья опубликована в высокорейтинговом журнале

Информация о цитировании статьи получена из Web of Science, Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 17 августа 2021 г.

Авторы: Guo Yu, Huang Lisu, Zhang Guangshun, Yao Yanfeng, Zhou He, Shen Shu, Shen Bingqing, Li Bo, Li Xin, Zhang Qian, Chen Mingjie, Chen Da, Wu Jia, Fu Dan, Zeng Xinxin, Feng Mingfang, Pi Chunjiang, Wang Yuan, Zhou Xingdong, Lu Minmin, Li Yarong, Fang Yaohui, Lu Yun-Yueh, Hu Xue, Wang Shanshan, Zhang Wanju, Gao Ge, Adrian Francisco, Wang Qisheng, Yu Feng, Peng Yun, Gabibov Alexander G., Min Juan, Wang Yuhui, Huang Heyu, Stepanov Alexey, Zhang Wei, Cai Yan, Liu Junwei, Yuan Zhiming, Zhang Chen, Lou Zhiyong, Deng Fei, Zhang Hongkai, Shan Chao, Schweizer Liang, Sun Kun, Rao Zihe
Журнал: Nature communications
Том: 12
Номер: 1
Год издания: 2021
Издательство: Nature Pub. Group
Местоположение издательства: United Kingdom
Номер статьи: 2623
DOI: 10.1038/s41467-021-22926-2
Аннотация: COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can provide an important treatment option to fight COVID-19, especially for the most vulnerable populations. In this work, potent antibodies binding to SARS-CoV-2 Spike protein were identified from COVID-19 convalescent patients. Among them, P4A1 interacts directly with and covers majority of the Receptor Binding Motif of the Spike Receptor-Binding Domain, shown by high-resolution complex structure analysis. We further demonstrate the binding and neutralizing activities of P4A1 against wild type and mutant Spike proteins or pseudoviruses. P4A1 was subsequently engineered to reduce the potential risk for Antibody-Dependent Enhancement of infection and to extend its half-life. The engineered antibody exhibits an optimized pharmacokinetic and safety profile, and it results in complete viral clearance in a rhesus monkey model of COVID-19 following a single injection. These data suggest its potential against SARS-CoV-2 related diseases.
Добавил в систему: Тарасова Елена Владимировна

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ЦЭМИ РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ЦЭМИ РАН

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomesстатья